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Abstract:
The goal of this study was to determine the long-term prognostic value of coronary computed
tomography angiography (CTA) among patients with diabetes mellitus (DM) compared with
nondiabetic subjects.The long-term prognostic value of coronary CTA in patients with DM is not
well established.Patients enrolled in the CONFIRM (Coronary CT Angiography Evaluation for
Clinical Outcomes: An International Multicenter) registry with 5-year follow-up data were identified.
The extent and severity of coronary artery disease (CAD) were analyzed at baseline coronary CTA
and in relation to outcomes between diabetic and nondiabetic patients. CAD according to coronary
CTA was defined as none (0% stenosis), nonobstructive (1% to 49% stenosis), or obstructive
(≥50% stenosis). Time to death (and in a subgroup, time to major adverse cardiovascular event)
was estimated by using multivariable Cox proportional hazards models.A total of 1,823 patients
were identified as having DM with 5-year clinical follow-up and were propensity-matched to 1,823
patients without DM (mean age 61.8 ± 10.9 years; 54.4% male). Patients with DM did not exhibit
a heightened risk of death compared with the propensity-matched nondiabetic subjects in the
absence of CAD on coronary CTA (risk-adjusted hazard ratio [HR] of DM: 1.32; 95% confidence
interval [CI]: 0.78 to 2.24; p = 0.296). Patients with DM were at increased risk of dying compared
with nondiabetic subjects in the setting of nonobstructive CAD (in the propensity-matched cohort:
HR, 2.10; 95% CI: 1.43 to 3.09; p < 0.001) with a mortality risk greater than nondiabetic subjects
with obstructive disease (p < 0.001). In a risk-adjusted hazard analysis among patients with DM,
both per-patient obstructive CAD and nonobstructive CAD conferred an increase in all-cause
mortality risk compared with patients without atherosclerosis on coronary CTA (nonobstructive
disease-HR: 2.07; 95% CI: 1.33 to 3.24; p = 0.001; obstructive disease-HR: 2.22; 95% CI: 1.47
to 3.36; p < 0.001).Among patients with DM, nonobstructive and obstructive CAD according
to coronary CTA were associated with higher rates of all-cause mortality and major adverse
cardiovascular events at 5 years, and this risk was significantly higher than in nondiabetic subjects.
Importantly, patients with DM without CAD according to coronary CTA were at a risk comparable
to that of nondiabetic subjects.
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ABSTRACT
OBJECTIVES The goal of this study was to determine the long-term prognostic value of coronary computed
tomography angiography (CTA) among patients with diabetes mellitus (DM) compared with nondiabetic subjects.
BACKGROUND The long-term prognostic value of coronary CTA in patients with DM is not well established.
METHODS Patients enrolled in the CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An Interna-
tional Multicenter) registry with 5-year follow-up data were identiﬁed. The extent and severity of coronary artery disease
(CAD) were analyzed at baseline coronary CTA and in relation to outcomes between diabetic and nondiabetic patients.
CAD according to coronary CTA was deﬁned as none (0% stenosis), nonobstructive (1% to 49% stenosis), or obstructive
($50% stenosis). Time to death (and in a subgroup, time to major adverse cardiovascular event) was estimated by using
multivariable Cox proportional hazards models.
RESULTS A total of 1,823 patients were identiﬁed as having DM with 5-year clinical follow-up and were propensity-
matched to 1,823 patients without DM (mean age 61.8  10.9 years; 54.4% male). Patients with DM did not exhibit a
heightened risk of death compared with the propensity-matched nondiabetic subjects in the absence of CAD on coronary
CTA (risk-adjusted hazard ratio [HR] of DM: 1.32; 95% conﬁdence interval [CI]: 0.78 to 2.24; p ¼ 0.296). Patients with
DM were at increased risk of dying compared with nondiabetic subjects in the setting of nonobstructive CAD (in the
propensity-matched cohort: HR, 2.10; 95% CI: 1.43 to 3.09; p < 0.001) with a mortality risk greater than nondiabetic
subjects with obstructive disease (p < 0.001). In a risk-adjusted hazard analysis among patients with DM, both per-
patient obstructive CAD and nonobstructive CAD conferred an increase in all-cause mortality risk compared with patients
without atherosclerosis on coronary CTA (nonobstructive disease—HR: 2.07; 95% CI: 1.33 to 3.24; p ¼ 0.001; obstructive
disease—HR: 2.22; 95% CI: 1.47 to 3.36; p < 0.001).
CONCLUSIONS Among patients with DM, nonobstructive and obstructive CAD according to coronary CTA were
associated with higher rates of all-cause mortality and major adverse cardiovascular events at 5 years, and this risk was
signiﬁcantly higher than in nondiabetic subjects. Importantly, patients with DM without CAD according to coronary
CTA were at a risk comparable to that of nondiabetic subjects. (J Am Coll Cardiol Img 2016;-:-–-) © 2016 by the
American College of Cardiology Foundation.
From the aDepartment of Radiology and Division of Cardiology, University of British Columbia, Vancouver, British Columbia,
Canada; bDepartment of Cardiology, Icahn School of Medicine at Mount Sinai, New York, New York; cDepartment of Imaging,
Cedars-Sinai Medical Center, Los Angeles, California; dDepartment of Medicine, University of Erlangen, Erlangen, Germany;
eDepartment of Medicine, Harbor–UCLA Medical Center, Los Angeles, California; fTennessee Heart and Vascular Institute,
Hendersonville, Tennessee; gDepartment of Medicine, Wayne State University, Henry Ford Hospital, Detroit, Michigan;
J A C C : C A R D I O V A S C U L A R I M A G I N G VO L . - , N O . - , 2 0 1 6
ª 2 0 1 6 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O UN DA T I O N
P U B L I S H E D B Y E L S E V I E R
I S S N 1 9 3 6 - 8 7 8 X / $ 3 6 . 0 0
h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c m g . 2 0 1 5 . 1 2 . 0 2 7
T he prevalence of diabetes mellitus(DM) is increasing rapidly due to agrowing obesity epidemic and an
aging Western population (1). Incremental
cardiovascular risk associated with DM over
the short term has been documented in
both single-center studies and through the
CONFIRM (Coronary CT Angiography Evalua-
tion for Clinical Outcomes: An International
Multicenter) registry (2). In addition, it has
been shown that coronary stenosis confers
additive risk prediction beyond both calcium
scoring and nonobstructive disease on coronary
computed tomography angiography (CTA) over short-
to intermediate-term follow-up (3).
To date, the prognostic value of CTA in patients
with DM over the long term has not been well eluci-
dated, with current knowledge limited to small
single-center studies (4,5). In addition, the relative
risk of patients with DM with both nonobstructive
and obstructive disease on coronary CTA compared
with nondiabetic subjects over the long term is un-
known. We accordingly performed an analysis to
determine the long-term prognostic value of coronary
CTA among patients with DM compared with nondi-
abetic subjects in a large, prospective, multicenter
international coronary CTA registry (CONFIRM).
MATERIALS AND METHODS
The CONFIRM registry is a prospective, international,
multicenter registry designed to evaluate the rela-
tionship of coronary atherosclerosis and clinical risk
factors to adverse outcomes among patients who
have undergone at least 64-slice clinically indicated
coronary CTA. The rationale and design of CONFIRM
have been reported previously (6). For the present
analysis, the primary study cohort comprised patients
included in the CONFIRM registry with 5-year follow-
up (all-cause mortality) and DM but no history of
known coronary artery disease (CAD) (myocardial
infarction or revascularization before the scan date).
A subgroup analysis was also performed among pa-
tients with 5-year major adverse cardiovascular event
(MACE) follow-up. For comparison, a propensity-
matched cohort of patients without DM or a history
of known CAD who also had 5-year follow-up were
identiﬁed.
CLINICAL EVALUATION AND CARDIAC RISK FACTOR
DEFINITIONS. Patient symptoms were assessed
before undergoing coronary CTA and deﬁned using
Diamond and Forrester criteria (7) according to the
American College of Cardiology guidelines for chest
pain assessment (8). Pre-test cardiovascular risk was
deﬁned using the Morise score (9). The presence of
cardiac risk factors was also prospectively assessed
before the coronary CTA. DM was deﬁned according
to a previous diagnosis made by a physician (using a
fasting glucose threshold of 126 mg/dl) and/or use of
insulin or oral hypoglycemic agents. Systemic arterial
hypertension was deﬁned as a documented history of
high blood pressure or treatment with antihyperten-
sive medications. Dyslipidemia was deﬁned as known
but untreated dyslipidemia or current treatment
with lipid-lowering medications. A positive smoking
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ABBR EV I A T I ON S
AND ACRONYMS
CAD = coronary artery disease
CI = conﬁdence interval
CTA = computed tomography
angiography
DM = diabetes mellitus
MACE = major adverse
cardiovascular event
HR = hazard ratio
LM = left main
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history was deﬁned as current smoking or cessation
of smoking within 3 months of testing. Family history
of premature coronary heart disease was determined
by patient query. Symptom presentation was classi-
ﬁed into 1 of 4 categories: typical angina, atypical
angina, noncardiac pain, or asymptomatic.
DATA ACQUISITION, IMAGE RECONSTRUCTION,
AND CTA ANALYSIS. Coronary CTA scanners used in
the CONFIRM registry and data acquisition for CTA
have been described in detail previously (10). Stan-
dardized protocols for image acquisition, as deﬁned
by the Society of Cardiovascular Computed Tomog-
raphy, were used at all participating sites. Image
interpretation was uniformly performed at each site
according to the society’s guidelines (11) by experi-
enced observers with level III (or equivalent)
accreditation and/or board certiﬁcation in cardiovas-
cular computed tomography. Each site applied stan-
dard anatomic segmental analysis for image
interpretation. All segments were coded for the
presence and severity of coronary stenosis and were
scored as normal (0% luminal stenosis), non-
obstructive (1% to 49% luminal stenosis), or
obstructive ($50% luminal stenosis). Stenoses were
assessed on a per-patient and per-vessel (left main
[LM]; left anterior descending, left circumﬂex, and
right coronary artery) basis.
FOLLOW-UP. The primary endpoint was time to
death from all causes. The secondary endpoint was
time to occurrence of major adverse cardiac event
(MACE), deﬁned as death, myocardial infarction, un-
stable angina, or late coronary revascularization (>90
days) in a subgroup of 973 patients with DM for whom
this information was available.
Follow-up procedures were approved by all study
centers’ institutional review boards. Death status for
non-U.S. centers was gathered by using clinical visits,
telephone contacts, and questionnaires sent by mail;
all reported events were veriﬁed by hospital records
or direct contact with a patient’s attending physician.
Death status for U.S. centers was ascertained either
by query of the Social Security Death Index or by
direct physician and/or patient contact.
STATISTICAL ANALYSIS. Stata version 14.0 (Stata
Corp, College Station, Texas) was used for all statis-
tical analyses. Categorical variables are presented as
frequencies (percentages) and continuous variables
as mean  SD. Time to death from all causes and
death rates as well as time to MACE and MACE rates
were calculated using univariable Cox proportional
hazards models. In each case, the proportional haz-
ards assumption was assessed using Schoenfeld re-
siduals. Patients with early revascularization were
censored from the prognosis analyses for the MACE
endpoint. Overall survival and MACE-free survival
among stenosis groups are presented using Kaplan-
Meier survival curves and compared using the log-
rank test.
For comparison versus the group with DM, a pro-
pensity score was developed from the predicted
probabilities of a multivariable logistic regression
model predicting DM from age, sex, hypertension,
dyslipidemia, smoking history, and family history. A
total of 1,823 patients with DM were matched to 1,823
nondiabetic subjects on the basis of this propensity
score using the Mahalanobis nearest-neighbor
matching algorithm with a caliper <0.001 (12). In all
matched patients, the balancing property was
satisﬁed.
Univariable Cox models were then used to compare
mortality risk between patients with DM and
propensity-matched nondiabetic subjects. Within
both the diabetic and nondiabetic groups, mortality
risk was assessed by using multivariable Cox models
with adjustment for age, sex, hypertension, dyslipi-
demia, family history, and current smoking; the
resulting hazard ratios (HR) and 95% conﬁdence in-
tervals (CIs) are reported. A 2-tailed p value <0.05 is
considered statistically signiﬁcant.
RESULTS
STUDY POPULATION. From the long-term cohort of
the CONFIRM registry, 5-year follow-up data were
available in 12,086 patients; 1,823 patients were
identiﬁed as having DM and no known prior CAD
TABLE 1 Demographic and Baseline Clinical Characteristics
Patients With
DM
(n ¼ 1,823)
Nondiabetic
Subjects
(n ¼ 1,823) p Value
Age, yrs 61.7  11.2 61.8  10.9 0.944
Male 986 (54.1) 992 (54.4) 0.842
BMI (n ¼ 5,566; 2,003), kg/m2 28.8  5.9 27.1  4.5 <0.001
Cardiac risk factors
Hypertension 1,384 (75.9) 1,373 (75.3) 0.671
Dyslipidemia 1,192 (65.4) 1,182 (64.8) 0.728
Smoking 391 (21.6) 385 (21.1) 0.808
Family history of coronary
artery disease
677 (37.7) 667 (36.6) 0.731
History of PAD 57 (7.7) 45 (6.6) 0.417
Chest pain 0.002 (overall)
No chest pain 389 (24.2) 486 (30.2) <0.001
Noncardiac chest pain 291 (18.1) 272 (16.9) 0.352
Atypical chest pain 547 (34.1) 496 (30.8) 0.046
Typical chest pain 379 (23.6) 358 (22.2) 0.348
Values are mean  SD or n (%).
DM ¼ diabetes mellitus; PAD ¼ peripheral arterial disease.
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(mean age 62  11 years; 54% male; mean follow-up
5.2  1.6 years). A propensity-matched cohort of
1,823 patients (mean age 62  11 years; 54% male;
mean follow-up 5.5  1.4 years) was selected from
8,407 patients without DM or known CAD and with
complete age, sex, and stenosis information. Patient
demographic characteristics and symptom status are
presented in Table 1.
PREVALENCE OF CAD. Overall, 443 (24%) of 1,823
patients with DM had no evidence of CAD on coronary
CTA. Nonobstructive CAD was present in 425 (23%)
patients and obstructive CAD in 955 (52%) patients
(1-, 2-, and 3-vessel/LM disease in 433 [24%], 239
[13%], and 283 [16%] patients, respectively) (Figure 1).
Among the 1,823 nondiabetic subjects, 531 (29%) had
no evidence of CAD on coronary CTA. Nonobstructive
CAD was present in 554 (30%) patients and obstruc-
tive CAD in 738 (40%) patients (1-, 2-, and 3-vessel/LM
disease in 366 [20%], 182 [10%], and 190 [10%]
patients).
CLINICAL OUTCOMES. Death occurred in 382 (10.5%)
of 3,646 patients (136 [7.5%] nondiabetic subjects;
246 [13.5%] patients with DM), with an annualized
mortality rate of 0.020 per person-year (95% conﬁ-
dence interval [CI]: 0.018 to 0.022) overall, 0.027
(95% CI: 0.024 to 0.031) in patients with DM, and
0.014 (95% CI: 0.012 to 0.016) in nondiabetic subjects.
The absence of CAD according to coronary CTA was
associated with a low overall annual mortality rate of
0.010 (95% CI: 0.008 to 0.013). In a risk-adjusted
hazard analysis, both per-patient obstructive and
nonobstructive CAD conferred an increase in all-
cause mortality risk compared with patients without
atherosclerosis on coronary CTA in patients with DM
(nonobstructive disease—HR: 2.07; 95% CI: 1.33 to
3.24; p ¼ 0.001; obstructive disease—HR: 2.22; 95% CI:
1.47 to 3.36; p < 0.001).
Kaplan-Meier all-cause mortality curves stratiﬁed
according to the presence and severity of coronary
CTA ﬁndings in patients with DM are shown in
Figure 2. In a risk-adjusted hazard analysis based on
the extent of CAD, a worsened all-cause mortality
prognosis was identiﬁed with a greater number of
coronary vessels with obstructive CAD in the DM
population (Table 2). Importantly, risk-adjusted
mortality was increased among patients with non-
obstructive CAD compared with patients without
evidence of CAD (p ¼ 0.001).
RELATIVE RISK IN DM PATIENTS VERSUS NONDIABETIC
SUBJECTS. Patients with DM exhibited no heightened
risk of death compared with nondiabetic subjects in
the absence of CAD on coronary CTA (p ¼ 0.310). The
risk of all-cause mortality was increased for patients
with DM compared with nondiabetic subjects for
both nonobstructive (HR: 2.10; 95% CI: 1.43 to 2.09;
p < 0.001) and obstructive disease, with a poorer
prognosis in patients with increasing severity of CAD
FIGURE 2 Risk-Adjusted Kaplan-Meier Curve for Survival on the Basis of CAD Severity
(None, Nonobstructive, or Obstructive) Among Patients With DM
1.00
0.95
0.90
0.85
0.80
0.75
6420
Years
No CAD Non-Obs CAD Obs CAD
Adjusted Kaplan-Meier curve for survival on the basis of CAD severity among patients with
DM and nondiabetic subjects. (A) Risk adjusted; (B) unadjusted. Obs ¼ obstructive; other
abbreviations as in Figure 1.
FIGURE 1 Extent and Severity of CAD on CTA in a Propensity-Matched Cohort of
Nondiabetic Subjects and Patients With DM
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
All Patients
(N = 3,646)
Diabetics
(N = 1,823)
Non-diabetics
(N = 1,823)
13% 16%
13%
24%
23%
24%
10%
10%
20%
30%
29%
12%
22%
27%
27%
3 VD/LM
2 VD
1 VD
Non-obstructive
None
Disease extent and severity on coronary computed tomography angiography (CTA) across
propensity-matched patients with diabetes mellitus (DM) and nondiabetic subjects
(p < 0.001). CAD ¼ coronary artery disease; LM ¼ left main; VD ¼ vessel disease.
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(Table 3). The presence of nonobstructive disease
conferred a particularly poor prognosis in patients
with DM, with no signiﬁcant difference in survival
observed among diabetic patients with non-
obstructive CAD compared with those with 1-vessel
CAD (p ¼ 0.403), 2-vessel CAD (p ¼ 0.257), or 3-
vessel/LM CAD (p ¼ 0.232) (Figure 3).
MACE OCCURRENCE IN THE COHORT WITH DM.
Follow-up data on occurrence of MACE were available
in 973 of 1,823 patients with DM. When early revas-
cularization was censored, MACE (inclusive of late
revascularization) occurred in 209 (32%) patients,
with 71 (11%) patients experiencing myocardial
infarction. The absence of CAD according to coronary
CTA was associated with a lower annualized MACE
rate of 0.013 (95% CI: 0.008 to 0.021) compared with
the overall annual MACE rate for the entire cohort of
0.068 (95% CI: 0.059 to 0.077). In a risk-adjusted Cox
analysis, both per-patient obstructive and non-
obstructive CAD conferred an increase in MACE risk
over those without atherosclerosis on coronary CTA
(nonobstructive disease—HR: 4.95; 95% CI: 2.85 to
8.59; p < 0.001; obstructive disease—HR: 10.51; 95%
CI: 6.12 to 18.06; p < 0.001). Kaplan-Meier curves for
MACE-free survival stratiﬁed according to the pres-
ence and severity of coronary CTA ﬁndings are
illustrated in Figures 4A and 4B, respectively. In a
risk-adjusted hazard analysis based on the extent of
CAD, a dose–response relationship between the
number of coronary vessels exhibiting obstructive
CAD and MACE occurrence was noted (Table 4). In
addition, the worsened prognosis associated with
extent of CAD held true across symptom status and
type (Table 5).
DISCUSSION
To the best of hour knowledge, our analysis repre-
sents the largest evaluation of the long-term prog-
nostic value of coronary CTA–identiﬁed CAD in
patients with DM. The main ﬁndings of our analysis
are that when propensity-matched to nondiabetic
subjects, those with DM without atherosclerosis have
a similar prognosis; however, their survival proba-
bility according to coronary CTA is signiﬁcantly worse
in the setting of any atherosclerotic disease. In fact,
patients with DM with nonobstructive CAD have a
signiﬁcantly worsened survival than those without
atherosclerosis and is comparable to patients with DM
with 1-vessel obstructive disease and to nondiabetic
subjects with multivessel obstructive CAD. Our re-
sults emphasize that the anatomic ﬁndings of CAD
according to coronary CTA confers important long-
term prognostic information, permitting accurate
risk stratiﬁcation of these patients.
The impact of nonobstructive disease in patients
with DM at long-term follow-up is much more
TABLE 3 Relative Risk for All-Cause Mortality in Patients With
DM Compared With Propensity-Matched Nondiabetic Subjects
Stratiﬁed According to Extent and Severity of CAD
HR for Patients
With DM Versus
Nondiabetic
Subjects 95% CI p Value
No CAD DM 1.31 0.78–2.22 0.310
Nonobstructive CAD DM 2.09 1.43–3.06 <0.001
Obstructive CAD DM 1.95 1.46–2.61 <0.001
1-Vessel obstructive CAD DM 1.48 0.95–2.29 0.080
2-Vessel obstructive CAD DM 2.45 1.36–4.40 0.003
3-Vessel/LM obstructive
CAD DM
2.31 1.35–3.94 0.002
Abbreviations as in Table 2.
FIGURE 3 Risk-Adjusted Kaplan-Meier Curve for All-Cause Mortality
1.00
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1VD 2VD 3VD/LMNo CAD Non-Obs CAD
Risk-adjusted Kaplan-Meier curve for survival on the basis of CAD severity (none,
nonobstructive, and 1-, 2- or 3-vessel/left main disease) among patients with DM.
Obs ¼ obstructive; other abbreviations as in Figure 1.
TABLE 2 Risk-Adjusted HR for All-Cause Mortality Among
Patients With DM According to Extent of CAD
HR* 95% CI p Value
No CAD 1.00
Nonobstructive CAD 2.09 1.34–3.27 0.001
1-Vessel obstructive CAD 1.79 1.13–2.85 0.013
2-Vessel obstructive CAD 2.61 1.61–4.23 <0.001
3-Vessel/LM obstructive CAD 2.61 1.63–4.20 <0.001
*Risk-adjusted for age, sex, hypertension, dyslipidemia, family history, and current
smoking.
CAD ¼ coronary artery disease; CI ¼ conﬁdence interval; DM ¼ diabetes
mellitus; HR ¼ hazard ratio; LM ¼ left main.
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profound than in previous analyses from the same
registry at 2.3 years (2,3,5,6), which have consistently
shown that obstructive disease confers a greater in-
cremental risk than nonobstructive disease across
many patient populations. There are many potential
explanations for this observation. It is a widely held
perception that vulnerable plaques often result in
MACE during a period of only modest plaque size and
luminal encroachment, supported by historical data
that up to two-thirds of acute coronary syndromes
occur in this setting (13). This belief developed from
several retrospective studies which showed that in
patients who underwent invasive angiography
months to years in advance of myocardial infarction,
the culprit lesion was most commonly angiographic-
ally mild (13–17). Longer follow-up may therefore
provide adequate time for plaque progression and
rapid luminal encroachment, resulting in the devel-
opment of both symptoms and potentially MACE.
Another explanation may be that post-CTA revascu-
larization of those patients with obstructive CAD
resulted in improved clinical outcomes. Although this
mechanism remains possible, angiographic-guided
revascularization of patients with DM has not been
shown to improve clinical outcomes compared with
medical therapy alone (18). The exact cause for the
apparent merging of clinical outcomes of those pa-
tients with nonobstructive disease and those with
single-vessel obstructive disease cannot be stated
with certainty; however, our data strongly suggest
that nonobstructive disease is of signiﬁcant long-term
prognostic importance in patients with DM.
Another important observation from our analysis is
that patients with DM without plaque had a compa-
rable risk of both MACE and death compared with
nondiabetic subjects without CAD according to coro-
nary CTA. In addition, although a common assump-
tion would be that only a small percentage of patients
with DM do not have CAD, in our cohort of >1,800
patients, approximately 1 in 4 had no computed
tomographic evidence of CAD. The comparable clin-
ical outcomes among patients with DM and nondia-
betic subjects without CAD, as well as the
signiﬁcantly worsened prognosis of patients with DM
with nonobstructive disease comparable to nondia-
betic subjects with multivessel obstructive disease,
warrant further investigation. This paradox may
inform future trials to determine the potential role of
aggressive therapy for atherosclerosis prevention in
the diabetic population. The potential beneﬁt of
aggressive medical therapy was recently highlighted
by the FACTOR-64 Trial (19). Patients in FACTOR-64
had medical care optimized in advance of enroll-
ment with an event rate that was substantially lower
than realized in our cohort. Although there are almost
certainly many factors that may help explain this
discordance, it highlights the potential differences
between standard and regulated optimal medical
care. The CONFIRM registry represents a broad,
global, real-world registry with medical therapy
TABLE 4 Risk-Adjusted HR for MACE Among Patients With DM
and Nondiabetic Subjects According to Extent of CAD
HR* 95% CI p Value
Diabetic patients
No CAD 1.00
Nonobstructive CAD 5.12 2.95–8.88 <0.001
1-Vessel obstructive CAD 8.15 4.57–14.53 <0.001
2-Vessel obstructive CAD 9.03 4.77–17.11 <0.001
3-Vessel/LM obstructive CAD 24.76 13.48–45.51 <0.001
Nondiabetic subjects
No CAD 1.00
Nonobstructive CAD 1.34 0.81–2.23 0.252
1-Vessel obstructive CAD 3.90 2.31–6.61 <0.001
2-Vessel obstructive CAD 4.47 2.39–8.36 <0.001
3-Vessel/LM obstructive CAD 4.30 2.22–8.35 <0.001
*Risk-adjusted for age, sex, hypertension, dyslipidemia, family history, and current
smoking.
MACE ¼ major adverse cardiovascular event; other abbreviations as in Table 2.
FIGURE 4 Risk-Adjusted Kaplan-Meier Curve for Event-Free Survival Stratiﬁed
According to CAD
DiabeticsA 1.00
0.80
0.60
0.40
0.20
0.00
6420 Years
M
A
CE
-fr
ee
 S
ur
vi
va
l P
ro
ba
bi
lit
y
No CAD
Non-Obst CAD
Obst CAD
B
No CAD
Non-Obst CAD
1VD
2VD
3VD/LM
1.00
0.80
0.60
0.40
0.20
0.00
6420 Years
M
A
CE
-fr
ee
 S
ur
vi
va
l P
ro
ba
bi
lit
y
(A) CAD presence assessed as none, nonobstructive, or obstructive disease. (B) CAD
severity assessed as none, nonobstructive, and 1-, 2- or 3-vessel/left main disease among
patients with DM. Obs ¼ obstructive; other abbreviations as in Figure 1.
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managed at the discretion of the individual
practitioner.
STUDY LIMITATIONS. Although this study involved a
large, multicenter international cohort, inherent
referral biases remain that plague any real-world
registry. Our study ﬁndings are derived from a
cohort of patients who underwent imaging rather
than from a cohort of stable patients with DM and
suspected CAD who may or may not be referred
clinically for further testing. Although risk factor
ascertainment was carefully and prospectively per-
formed, the downstream treatment of patients in our
cohort remains unknown. Potential downstream
treatment biases may have altered the rates of MACE
on the basis of the baseline CAD extent and severity.
Finally, not all patients had MACE-related follow-up,
which is lowered further owing to the required
censoring of early revascularization procedures.
CONCLUSIONS
Coronary CTA–identiﬁed atherosclerotic disease, both
nonobstructive and obstructive in nature, confers
important long-term prognostic information in pa-
tients with DM. Importantly, patients with DM
without atherosclerosis according to coronary CTA
have a comparable prognosis to nondiabetic subjects,
but in the setting of both nonobstructive and
obstructive disease, they have a signiﬁcantly wors-
ened prognosis.
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